Status:

RECRUITING

Online COgnitive Behavioural Therapy for Sleep and Mental Health for Older Adults With Insomnia and Subjective Cognitive Complaints

Lead Sponsor:

Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal

Conditions:

Insomnia

Eligibility:

All Genders

60-99 years

Phase:

NA

Brief Summary

The goal of this randomized controlled clinical trial is to assess a novel cognitive-behavioral program for sleep and mental health using a multidomain web platform (eCBTi+) in participants with insom...

Detailed Description

Participants with insomnia disorder will complete: * A phone interview * Two video conferences (assessment of eligibility and tutorial to set up sleep monitoring devices) * 9 nights of at-home polyso...

Eligibility Criteria

Inclusion

  • Inclusion
  • age 60 years or older at the time of enrolment
  • Sleep Condition Indicator, SCI ≤ 16 and/or meeting DSM-V criteria based on the symptoms assessed by the SCI
  • subjective cognitive complaints (self-report version of Everyday Cognition scale (ECog), score ≥ 2 on any item)
  • ability to read and understand French or English
  • ability to use a smartphone or tablet, and access to home internet connection
  • If on hypnotic or psychotropic medication (including cannabis), being on stable dosage for at least 2 months prior to study entry
  • Score on the STOP-BANG questionnaire \< 3 corresponding to participants with low risk of obstructive sleep apnea
  • Exclusion
  • located outside of Québec or Ontario
  • current hospitalization or planned major surgery
  • uncorrected severe hearing or vision impairment
  • reported diagnosis of major neurocognitive disorder or mild cognitive impairment (MCI)
  • performance suggestive of major neurocognitive disorder or MCI on T-MoCA \< 17
  • reported diagnosis of schizophrenia or bipolar disorder
  • reported diagnosis or positive screen on the MINI for psychotic or bipolar disorders
  • high suicidal risk, as assessed by the modified Columbia-Suicide Severity Rating Scale
  • reported diagnosis or positive screening (apnea-hypopnea index \>30 on a level 3 home sleep apnea test) for another untreated sleep disorder (e.g., sleep disordered breathing (OSA), REM sleep behavior disorder (RBD), restless legs syndrome (RLS); individuals with treated and controlled OSA (residual apnea-hypopnea index \<30 and good therapeutic compliance) or RLS will not be excluded
  • current shift work
  • currently receiving CBT, having received CBTi in the past
  • frequent alcohol consumption having an impact on functionning (\>10 glasses/week and having a significant impact on functionning)
  • illicit drugs use (more than once a month)
  • Additional exclusion criteria for neuroimaging
  • psychotropic (including hypnotic) medication in the past 2 weeks
  • contraindications for MRI (e.g., pacemaker, metallic implant, claustrophobia)
  • unable or unwilling to come to one of the participating MRI centers (Montreal, Ottawa)
  • medical conditions likely to affect sleep; in particular:
  • current neurological disorder (e.g., epilepsy with any seizure in the past year, concussion in the past 3 months, multiple sclerosis, Parkinson's disease)
  • past history of brain lesion (e.g., brain hemorrhage, brain tumor, any condition having required brain surgery)
  • major surgery (i.e., requiring general anesthesia) in the past 3 months
  • untreated thyroid disorder
  • chronic pain syndrome self-reported as interfering with sleep (e.g., migraine, fibromyalgia, rheumatoid arthritis)
  • recent and severe infection in the past 3 months (e.g., pneumonia, kidney infection)
  • active cancer or treated cancer with post-cancer treatment for less than 2 years
  • Inclusion/exclusion criteria for good sleepers Twenty-five good sleepers without cognitive complaint will be recruited as controls for the MRI session following the same criteria described above, except that SCI ≥ 17, not meeting the diagnostic criteria for chronic insomnia as assessed by the insomnia module of the SCID and no subjective cognitive complaint.

Exclusion

    Key Trial Info

    Start Date :

    November 15 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2025

    Estimated Enrollment :

    275 Patients enrolled

    Trial Details

    Trial ID

    NCT06032377

    Start Date

    November 15 2023

    End Date

    December 1 2025

    Last Update

    June 10 2025

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    The Royal's Institute of Mental Health Research (IMHR)

    Ottawa, Ontario, Canada, K1Z7K4

    2

    Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de l'Île-de-Montréal. CCSMTL - IUGM

    Montreal, Quebec, Canada, H3W 1W5